| FXN — Frataxin | |
|---|---|
| Symbol | FXN |
| Full Name | Frataxin |
| Chromosome | 9q21.11 |
| NCBI Gene | 2395 |
| Ensembl | ENSG00000165060 |
| OMIM | 606829 |
| UniProt | Q16595 |
| Diseases | Friedreich's Ataxia |
| Expression | Dorsal root ganglia, Spinal cord, Cerebellum, Heart, Pancreas, Liver |
| Key Mutations | |
| GAA repeat expansion (intron 1, 90–1300 repeats) p.I154F — missense p.G130V — missense p.W155R — missense p.L106S — missense |
|
Fxn — Frataxin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FXN (Frataxin) is a nuclear gene located on chromosome 9q21.11 that encodes the mitochondrial protein frataxin, an essential component of the iron-sulfur (Fe-S) cluster biosynthesis machinery [1].
Pathological expansion of a GAA trinucleotide repeat in intron 1 of FXN is the causative mutation in Friedreich's Ataxia (FRDA), the most common inherited ataxia, affecting approximately 1 in 50,000 individuals in
European populations [1][2].
The GAA expansion leads to epigenetic silencing of the FXN locus and dramatically reduced frataxin protein levels, resulting in mitochondrial iron accumulation, oxidative stress, and progressive neurodegeneration
predominantly affecting the dorsal root ganglia, cerebellum, and spinal cord [3].
The gene was identified in 1996 by Campuzano and colleagues, who discovered that Friedreich's Ataxia is caused by an intronic GAA triplet repeat expansion — the first example of a disease-causing intronic trinucleotide repeat [1]. FXN is catalogued as NCBI Gene ID [2395] and OMIM [606829].
The FXN gene spans approximately 95 kb of genomic DNA and contains seven exons encoding a 210-amino acid precursor protein [2].
Normal individuals carry 5–33 GAA repeats in intron 1, while affected individuals harbor 66–1,700 repeats on both alleles (homozygous expansion in ~96% of patients) or a GAA expansion on one allele and a point mutation
on the other (compound heterozygotes, ~4%) [1][4].
The frataxin precursor is synthesized in the cytoplasm and imported into the mitochondrial matrix, where it undergoes two-step proteolytic processing by mitochondrial processing peptidase (MPP) to yield the mature 130-amino acid (14 kDa) protein [2][5]. The mature frataxin adopts a compact α-β sandwich fold consisting of:
The acidic ridge on the α-helix and β-sheet surface coordinates iron binding and mediates protein-protein interactions with the Fe-S cluster assembly complex [5].
Frataxin is an essential activator of the mitochondrial iron-sulfur (Fe-S) cluster assembly complex, which consists of the cysteine desulfurase NFS1, its partner protein ISD11, the scaffold protein ISCU2, and frataxin itself [5]. Within this complex, frataxin:
Fe-S clusters are essential prosthetic groups for proteins involved in the mitochondrial electron transport chain (Complexes I, II, III), the citric acid cycle (aconitase), DNA repair, and numerous other cellular processes [3][5].
Frataxin contributes to cellular antioxidant defenses through multiple mechanisms:
Frataxin is expressed ubiquitously but is particularly abundant in tissues with high metabolic demands:
Expression data is available from the Allen Human Brain Atlas.
Friedreich's Ataxia (FRDA) is an autosomal recessive neurodegenerative and cardiac disease caused by insufficient frataxin protein [1].
The GAA repeat expansion in intron 1 induces heterochromatin formation through H3K9 trimethylation and DNA methylation, silencing FXN transcription and reducing frataxin levels to 5–30% of normal [2][6].
Clinical features develop typically in childhood or adolescence and include:
Longer GAA repeat expansions correlate with earlier onset, greater disease severity, and faster progression [1][4].
The inverse correlation between GAA repeat length and frataxin protein levels provides the mechanistic link between genotype and phenotype.
Approximately 4% of FRDA patients are compound heterozygotes, carrying a GAA expansion on one allele and a conventional point mutation or deletion on the other [4].
A 2024 study of phenotypic variation in compound heterozygotes found that non-GAA repeat mutations were associated with reduced cardiac disease, and patients with partial-function mutations showed relative sparing of
bulbar and upper limb function [4].
Reduced frataxin levels impair Fe-S cluster biosynthesis, leading to mitochondrial iron overload. Excess mitochondrial iron generates hydroxyl radicals via Fenton reactions, causing [oxidative damage] to mitochondrial DNA, lipids, and proteins [3]. This creates a vicious cycle: oxidative damage further impairs [mitochondrial function], which exacerbates iron dysregulation.
Fe-S clusters are essential cofactors for Complexes I, II, and III of the mitochondrial electron transport chain. Frataxin deficiency causes progressive loss of respiratory chain activity, reduced ATP production, and increased electron leakage generating superoxide [3][5].
The [selective vulnerability] of dorsal root ganglia neurons and cerebellar dentate nucleus neurons reflects their exceptionally high metabolic demands, large cell body size, long axons requiring extensive mitochondrial transport, and high dependence on Fe-S cluster-containing enzymes for proprioceptive signaling [3].
The study of Fxn — Frataxin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.